Recent randomized trials testing combined modality therapy that includes involved-field radiation therapy.
| Trial . | Chemotherapy . | Radiation Therapy . | Outcomes . | P value . |
|---|---|---|---|---|
| Abbreviations: EORTC, European Organization for Research and Treatment of Cancer; GHSG, German Hodgkin’s Study Group; EBVP, epirubicin, bleomycin, vinblastine, prednisone; ABVD, doxorubicin (Adriamycin®), bleomycin, vinblastine and dacarbazine; IF, involved field; EFS, event-free survival; OS, overall survival; FFTF, freedom from treatment failure | ||||
| EORTC H9F14 | EBVP, 6 cycles | IF 36 vs 20 Gy | 4-yr EFS: 87% vs 84% 4-yr OS: 98% vs 98% | No significant differences between groups |
| GHSG HD1015 | ABVD, 2 vs 4 cycles | IF 30 vs 20 Gy | Overall: FFTF 96.6% and OS 98.5% (median follow-up 2 years) | No significant differences between groups |
| Trial . | Chemotherapy . | Radiation Therapy . | Outcomes . | P value . |
|---|---|---|---|---|
| Abbreviations: EORTC, European Organization for Research and Treatment of Cancer; GHSG, German Hodgkin’s Study Group; EBVP, epirubicin, bleomycin, vinblastine, prednisone; ABVD, doxorubicin (Adriamycin®), bleomycin, vinblastine and dacarbazine; IF, involved field; EFS, event-free survival; OS, overall survival; FFTF, freedom from treatment failure | ||||
| EORTC H9F14 | EBVP, 6 cycles | IF 36 vs 20 Gy | 4-yr EFS: 87% vs 84% 4-yr OS: 98% vs 98% | No significant differences between groups |
| GHSG HD1015 | ABVD, 2 vs 4 cycles | IF 30 vs 20 Gy | Overall: FFTF 96.6% and OS 98.5% (median follow-up 2 years) | No significant differences between groups |